Status:
COMPLETED
To Demonstrate the Relative Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets
Lead Sponsor:
Sandoz
Conditions:
Allergy
Eligibility:
MALE
19-55 years
Phase:
PHASE1
Brief Summary
To demonstrate the relative bioequivalency study of dosage forms of Clemastine 2.68 mg tablets.
Eligibility Criteria
Inclusion
- No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
Exclusion
- Positive test results for HIV or hepatitis B or C.
- Treatment for drug or alcohol dependence.
Key Trial Info
Start Date :
December 1 1989
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 1990
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00913549
Start Date
December 1 1989
End Date
January 1 1990
Last Update
March 28 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.